FDAsafety guidance83% confidence
Phase 1 Investigational New Drug (IND) Navigator
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
The Phase 1 IND Navigator provides the tools, guidances, and regulatory expertise you need to prepare and submit an successful Investigational New Drug (IND) application.
Supporting Context
- Therapeutic area
- Oncology · Immunotherapy
- Sub-indication
- General
Related signal: Merck's MK-1045 Under Investigation for Non-Hodgkin Lymphoma Treatment